Terada S, Uchide K, Suzuki N, Akasofu K, Nishida E
Department of Obstetrics and Gynecology, Kanazawa University, School of Medicine, Japan.
Breast Cancer Res Treat. 1995 Apr;34(1):35-43. doi: 10.1007/BF00666489.
Postpartum Wistar inbred rats (weaned on the 9th puerperal day) were injected intraductally in one mammary gland with 7,12-dimethylbenze (a) anthracene (DMBA) to selectively induce ductal carcinoma. The incidence of ductal hyperplasia increased with time until it peaked at 7 weeks (12/13 animals) and then decreased. Ductal carcinoma first developed at 9 weeks in 3/12 (2 non-invasive and 1 invasive lesion) and the incidence increased with time until invasive ductal tumors were observed in 9/11 at 20 weeks. Tumors developed only in the DMBA-treated mammary glands and no systemic effects of the carcinogen were observed. Degeneration and detachment of epithelioglandular cells were seen here and there in the ducts and terminal ducts, and epithelioglandular cells proliferated in terminal duct until 2 weeks. Residual trace DMBA powder was detected in terminal ducts and the epithelioglandular layer until 7 weeks. This trace DMBA was considered to be the cause of the development of atypical epithelial cells, inducing ductal carcinomas.
产后Wistar近交系大鼠(产后第9天断奶)在一侧乳腺导管内注射7,12-二甲基苯并(a)蒽(DMBA)以选择性诱导导管癌。导管增生的发生率随时间增加,直至7周时达到峰值(13只动物中有12只),然后下降。导管癌在9周时首次出现,12只中有3只(2例非侵袭性病变和1例侵袭性病变),其发生率随时间增加,直至20周时11只中有9只观察到侵袭性导管肿瘤。肿瘤仅在接受DMBA处理的乳腺中发生,未观察到致癌物的全身影响。在导管和终末导管中可见上皮腺细胞的变性和脱落,终末导管中的上皮腺细胞在2周前增殖。直至7周,在终末导管和上皮腺层中检测到残留的微量DMBA粉末。这种微量DMBA被认为是导致非典型上皮细胞发展、诱发导管癌的原因。